[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365833-105":59,"doc-detail-365833-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ccat2-role-in-gastrointestinal-cancer-progression-and-metastasis-a-novel-target-for-therapeutic-strategies","CCAT2 role in gastrointestinal cancer progression and metastasis - a novel target for therapeutic strategies","","Long non-coding RNAs (lncRNAs) are over-200-nucleotide non-protein-coding transcripts whose aberrant expression contributes to tumor development. Abnormal lncRNA levels affect key cancer processes including proliferation, migration, invasion, metastasis, and epithelial–mesenchymal transition. Colon cancer-associated transcript 2 (CCAT2), an oncogenic lncRNA, has been reported as a prognostic biomarker across multiple cancers, with overexpression linked to tumor size, TNM stage, tumor progression, and poor clinical outcomes. This review summarizes evidence on CCAT2’s roles in colorectal, gastric, hepatocellular, and oropharyngeal cancers, its involvement in cancer-related molecular mechanisms, and its potential as a diagnostic and prognostic biomarker, highlighting CCAT2 as a novel therapeutic target in gastrointestinal cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ccat2-role-in-gastrointestinal-cancer-progression-and-metastasis-a-novel-target-for-therapeutic-strategies/365833/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ccat2-role-in-gastrointestinal-cancer-progression-and-metastasis-a-novel-target-for-therapeutic-strategies/365833.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is CCAT2 and why is it important in gastrointestinal cancers?","Question",{"text":112,"@type":113},"CCAT2 is a long non-coding RNA originally identified as an oncogene in colon cancer. Evidence links CCAT2 overexpression with tumor progression, metastasis-related processes, and poor clinical outcomes across gastrointestinal malignancies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CCAT2 relate to clinical prognosis and cancer progression?",{"text":117,"@type":113},"Studies summarized in the document report that CCAT2 overexpression correlates with tumor size, TNM stage, progression, and unfavorable clinical outcomes, supporting its role as a prognostic biomarker.",{"name":119,"@type":110,"acceptedAnswer":120},"What potential does CCAT2 have for diagnosis, prognosis, and therapy?",{"text":121,"@type":113},"The review evaluates CCAT2 as a diagnostic and prognostic biomarker in gastrointestinal patients. It also indicates CCAT2 can serve as a novel target for therapeutic strategies in gastrointestinal cancers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365833,1790319531,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Clinical and Experimental Medicine (2025) 25:197 [https://doi.org/10.1007/s10238-025-01730-y](https://doi.org/10.1007/s10238-025-01730-y)  \nCCAT2 role in gastrointestinal cancer progression and metastasis: a novel target for therapeutic strategies  \nAhmad GhorbaniVanan1 · Farid Ghorbaninezhad1 · Golnaz Nikeghbali2 · Fateme Mohamadi3 · Ariyan Ayati2 ·  \nReza Ghanbari Mastani4 · Zahra Shahhoseini2 · Pooya Eini5 · Ronak Ahmadi6 · SafaTahmasebi1 · Elham Safarzadeh7  \nReceived: 24 March 2025 / Accepted: 9 May 2025 / Published online: 11 June 2025 © The Author(s) 2025  \nAbstract  \nLong non-coding RNAs (lncRNAs) are a class of non-protein-coding RNAs that have over 200 nucleotides. Various studies have shown that aberrant expression of lncRNAs can lead to the development of different tumors. Furthermore, recent findings revealed that abnormal lncRNA expression can significantly influence cancer-related processes such as proliferation, migration, invasion, metastasis, and epithelial–mesenchymal transition. Colon cancer-associated transcript 2 (CCAT2), a type of lncRNA, was initially identified as an oncogene in colon cancer and subsequently identified as a prognostic biomarker in different cancers, including hepatocellular carcinoma, esophageal squamous cell carcinoma, ovarian cancer, lung cancer, breast cancer, and other tumors. Cumulative studies have revealed that the overexpression of CCAT2 is significantly correlated with tumor size, tumor node metastasis (TNM stage), tumor progression, and poor clinical outcomes. The significant role of CCAT2 in various gastrointestinal (GI) malignancies has drawn increased attention in recent years. In the present study, we reviewed recent literature concerning lncRNA CCAT2’s role in the development and progression of different GI cancers, including colorectal, gastric, hepatocellular, and oropharyngeal cancer, its interaction with cancer-related molecular mechanisms, and evaluate its potential as a diagnostic and prognostic biomarker in GI patients. In addition, this study shows that CCAT2 can be applied as a novel target for treatment strategies in gastrointestinal cancers.  \nKeywords Long non-coding RNA · lncRNA · Colon cancer-associated transcript 2 · CCAT2 · Gastrointestinal cancer  \nIntroduction  \n\n| Fateme Mohamadi, Ariyan Ayati and Reza Ghanbari Mastani have contributed equally. |\n| --- |\n| A. G. Vanan, F. Ghorbaninezhad and G. Nikeghbali: Co-first authors. |\n\n* Safa Tahmasebi[safa.tahmasebi@sbmu.ac.ir](safa.tahmasebi@sbmu.ac.ir)  \n* Elham Safarzadeh [Elham.im63@gmail.com](Elham.im63@gmail.com)  \n1 Student Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \n2 School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \n3 Department of Immunology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran  \nGastrointestinal cancers (GI cancers) depict a diverse assortment of conditions affecting the gastrointestinal system, mainly including laryngeal, gastric, esophageal, and colorectal cancers (CRCs) . Constituting over a quarter of the total cancer incidence, their occurrence is persistently on the rise [1]. In 2018, 5 million new cases were diagnosed with GI cancer, and nearly  \n4 School of Medicine, Iran University of Medical Sciences, Tehran, Iran  \n5 Toxicological Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \n6 Department of Pathobiology, Faculty of Veterinary, Tabriz Medical Sciences, Islamic Azad University, Tabriz, Iran  \n7 Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran  \n3 million related deaths were estimated by the GLOBOCAN database [2]. Trends among major GI cancers are different due to lifestyle changes; for example, gastric cancer (GC) prevalence is predicted to have a minor decrease over the next years [3], and CRC is anticipated to experience an escalation by 60% in ","cbCaijo90dgcGfhY","https://ap.wps.com/l/cbCaijo90dgcGfhY","pdf",1123526,"English","# Abstract\n## Introduction\n## Long non-coding RNAs and cancer biology\n## CCAT2 in gastrointestinal cancers","[{\"question\":\"What is CCAT2 and why is it important in gastrointestinal cancers?\",\"answer\":\"CCAT2 is a long non-coding RNA originally identified as an oncogene in colon cancer. Evidence links CCAT2 overexpression with tumor progression, metastasis-related processes, and poor clinical outcomes across gastrointestinal malignancies.\"},{\"question\":\"How does CCAT2 relate to clinical prognosis and cancer progression?\",\"answer\":\"Studies summarized in the document report that CCAT2 overexpression correlates with tumor size, TNM stage, progression, and unfavorable clinical outcomes, supporting its role as a prognostic biomarker.\"},{\"question\":\"What potential does CCAT2 have for diagnosis, prognosis, and therapy?\",\"answer\":\"The review evaluates CCAT2 as a diagnostic and prognostic biomarker in gastrointestinal patients. It also indicates CCAT2 can serve as a novel target for therapeutic strategies in gastrointestinal cancers.\"}]","CCAT2 role in gastrointestinal cancer progression and metastasis - a novel target for therapeutic strategies | PDF",1790162556,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8b0ddcc1af5840b2fddd52dd062b636.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f104a1f577b894c3b290c27a9cfda90.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c125407e37a85e5510e8df203df13bc8.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1a389cfcede542b6b28eec3410a17ce.webp",980,1301]